Novo Nordisk A/S (NYSE:NVO) Shares Bought by Schrum Private Wealth Management LLC

Schrum Private Wealth Management LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 100.0% during the 3rd quarter, Holdings Channel reports. The firm owned 4,804 shares of the company’s stock after buying an additional 2,402 shares during the period. Schrum Private Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $572,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of NVO. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S during the second quarter worth $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at $25,000. Orion Capital Management LLC purchased a new stake in Novo Nordisk A/S during the 1st quarter worth about $26,000. Gilliland Jeter Wealth Management LLC lifted its holdings in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. Finally, Halpern Financial Inc. lifted its stake in shares of Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NVO has been the topic of several analyst reports. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Trading Up 0.3 %

Shares of NYSE:NVO traded up $0.29 during trading on Wednesday, reaching $107.35. 956,590 shares of the stock were exchanged, compared to its average volume of 4,430,909. The firm’s 50-day moving average price is $120.23 and its 200 day moving average price is $130.08. The firm has a market cap of $481.74 billion, a price-to-earnings ratio of 34.68, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.